Browse the evidence

Success in weight loss was independent of the quantity and quality of carbohydrate intake.

Weight loss programs may not need to focus on carbohydrate quantity or quality.

The control group demonstrated a trend of gaining on average 0.37 ± 6.03 kg.

Regular care may not be effective for weight management compared to structured programs.

Subjects with the highest scores on the 'high-protein and high-carbohydrate' dietary patterns had higher odds of cardiovascular disease (CVD) than those with the lowest scores (OR: 2.89, 95% CI: 2.11–3.96).

Practitioners should consider advising patients with T2D to be cautious about high-protein and high-carbohydrate dietary patterns due to their association with increased CVD risk.

The dietary pattern of PCA-prudent was not significantly related to the odds of having CVD in T2D patients (adjusted OR: 0.93, 95% CI: 0.70–1.24).

This suggests that not all dietary patterns are equally associated with CVD risk, and practitioners should evaluate dietary recommendations accordingly.

Cost sharing does not contribute to better participation or weight loss relative to total subsidy.

Cost sharing may not be effective for improving long-term outcomes in weight-loss programs.

Resistance training tempo has minimal overall effect on muscle hypertrophy.

Practitioners may consider that varying resistance training tempo may not significantly impact muscle growth.

The evidence supporting the three scientific models of obesity that blame dietary macronutrients is mixed and sometimes false.

Practitioners should be cautious about attributing obesity to specific macronutrients without considering the mixed evidence.

The chapter reviews concepts of energy balance and macronutrient balance as applied to the human body.

Practitioners should incorporate energy and macronutrient balance concepts into their approaches to nutrition.

Short-term time-restricted feeding (TRF) does not significantly change supramaximal exercise performance.

Short-term TRF may not be beneficial for immediate performance improvements.

The cost-effectiveness of ILI over the 9-year period is unclear due to different health utility measures leading to different conclusions.

Practitioners should be cautious in interpreting the cost-effectiveness of lifestyle interventions due to variability in health utility measures.

There are three broadly different subtypes of vegan diets: vegan (general), raw food vegan, and whole food vegan.

Understanding the different subtypes of vegan diets can help practitioners tailor dietary advice.

Neither High Quality nor High Adherence alone were significantly different than the Low Quality/Low Adherence subgroups.

Focus on both dietary quality and adherence rather than either alone for weight loss strategies.

In China, there was no significant association between white rice intake and diabetes risk (HR: 1.05; 95% CI: 0.78-1.41, p for trend = 0.38).

Dietary recommendations regarding white rice may differ in China compared to other regions due to the lack of associated diabetes risk.

Weight loss magnitude was lower in patients taking GLP-1 RAs compared to postbariatric patients (29.9 kg vs 47.2 kg).

Understanding the differences in weight loss can help tailor interventions for patients seeking body contouring.

Systematic measurement of sexual desire should be prioritized in future research on GLP-1 agonists.

Researchers should include sexual desire as a key outcome in studies involving GLP-1 agonists.

Gastrointestinal complaints were common but did not significantly influence satisfaction ratings or decisions to continue treatment.

Practitioners should note that while gastrointestinal side effects are common, they may not deter patients from continuing treatment if weight loss is achieved.

A modified prolactin-releasing peptide, NN501, reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.

NN501 may be a viable alternative therapy for obesity management focusing on fatty acid oxidation.

Discontinuation rates for GLP-1 RAs can be up to 80% after 2 years.

Practitioners should be aware of high discontinuation rates when prescribing GLP-1 RAs.

LLM responses provided appropriate information about standard GLP1RA-related queries but lacked updated information on emerging concerns.

Practitioners should be aware that while LLMs can provide useful information, they may not reflect the latest developments in GLP1RA therapy.

Internet search responses were more heterogeneous and often commercially biased.

Practitioners should critically evaluate internet sources for GLP1RA information due to potential bias.

Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.

The effectiveness of semaglutide is consistent regardless of these common patient characteristics.

There were no significant differences in the amount of weight lost between semaglutide 0.5 mg and liraglutide 3 mg after 3 months.

Clinicians can expect similar weight loss outcomes from either treatment option.

Over half (60%) of participants with a BMI indicating obesity had no clinical diagnosis of obesity in their EHRs.

Clinicians should be aware that a significant number of patients with obesity may not be diagnosed, potentially leading to untreated health issues.

Men, and particularly NH-Asian men, may be at heightened risk of underdiagnosis of obesity.

Awareness of potential underdiagnosis in specific male populations can improve obesity management strategies.